Paul Langerhans Institute Dresden - PLID

New bioRxiv paper from the Solimena Lab: glucose-regulated binding of actin-modified villin to SNAP25 acts downstream of ICA512 retrograde signaling to control insulin granule access to exocytic docking sites in β cells. www.biorxiv.org/content/10.6...

YouTube video by TU Dresden entdecken Wie wird Insulin produziert? 🩸 | Kurze Frage über Diabetesforschung & Betazellen

The TUD has made a very nice video in their "Kurze Frage" series featuring PLID member Andreas Müller where he explains how insulin is produced by the beta cells of the pancreas and why this is important in diabetes (German only)

#TUDresden #DiabetesResearch #PLID #HelmholztzMunich

✨ Happy Postdoc Appreciation Week! ✨

Today we celebrated with cake, coffee, and reflections on postdoc life.

We’re so grateful for the dedication and passion our postdocs bring to advancing diabetes research. 👏 Thank you!

#PAW2025 #PostdocAppreciationWeek #DiabetesResearch

Beta cells hiding a neural secret? 🧠➡️🩸

See how @andimicroscopy.bsky.social used volume electron microscopy to reveal axo-ciliary synapses between beta cell cilia and pancreatic nerves—structures never before seen outside the brain!

Read more here 👉🏼 shorturl.at/EF3co

#DiabetesResearch #VolumeEM

🌎 What if we told you 1 in 10 people worldwide has diabetes?

In Germany, it’s already 8.9M — and the number could double by 2040. That’s why researchers at the PLID are working hard to understand the mechanisms driving diabetes.

Read more about the rise of diabetes here 👉🏼 shorturl.at/tLXIX

🚀 Excited to welcome Prof. Mikael Rydén for our upcoming #DiabetesResearchSeminar! 🧬

He’ll present: “𝘌𝘷𝘦𝘳𝘺𝘵𝘩𝘪𝘯𝘨 𝘺𝘰𝘶 𝘸𝘢𝘯𝘵 𝘵𝘰 𝘬𝘯𝘰𝘸 𝘢𝘣𝘰𝘶𝘵 𝘸𝘩𝘪𝘵𝘦 𝘢𝘥𝘪𝘱𝘰𝘴𝘦 𝘵𝘪𝘴𝘴𝘶𝘦.” Join us in exploring how fat tissue shapes metabolism, diabetes, and chronic disease.

#Diabetes #Research #Metabolism #AdiposeTissue

🚀 Join us for the next #DiabetesResearchSeminar with our guest Olof Idevall-Hagren, as we dive into the secret world of pancreatic β-cells! Discover how their inner workings shift in diabetes and the insights this holds for new type 2 diabetes therapies.

Here at the PLID, we are working to make diabetes research and data is FAIR: Findable, Accessible, Interoperable, and Reusable.
The FAIR guiding principles lead us toward more transparent data practices—because real progress happens when research is shareable, searchable, and sustainable. #FAIRData

Here’s our team hard at work sharing knowledge about diabetes with the public at the Long Night of Science! 🧬💬

We had tons of great conversations, including with a 12-year-old citizen scientist! 🧪 We also saw strong support for a sugar tax among our visitors. 🍬📉

#ScienceOutreach #DiabetesAwareness

Visit us at the Long Night of Sciences at the CBCB 1st floor to learn about our Diabetes research #LNDW @cmcb-tud.bsky.social

Don´t miss Andreas talk today‼️ He will be speaking about his volume EM work in pancreatic beta cells.
#DiabetesResearch #volumeEM #BetaCells
👇👇👇

Join us on June 24 at 3 PM (BCUBE, Dreseden) for Mark Huising’s talk: “Dynamic crosstalk within the islet determines insulin release” and learn how research into glucose homeostasis may reveal therapeutic targets for diabetes.
@huisinglab.bsky.social @ucdavis.bsky.social

Team PLID hit the streets for the 2025 REWE Team Challenge! 🏃‍♂️💪

We know how powerful movement is in preventing and managing diabetes. This 5K was more than a run—it was a step toward healthier lives, together. See you next year, Dresden!

#TeamPLID #DiabetesResearch #REWEChallenge2025 #DresdenRun

🌙 This year’s Long Night of Science is taking place on June 20 at the CRTD from 5pm to midnight — and we’ll be there! Come by our booth and explore the world of #diabetes research and chat with #scientists. 🔬🧬

Learn more👉 t1p.de/ezlaa

See you there!

#LNDWDD #Diabetes #DiabetesResearch

🚨New #DiabetesResearch led by Esteban Quezada from the Solimena lab shows that the RNA binding protein G3BP1 plays an important role in the storage of #insulin mRNA🧬 in the cytosol of #BetaCells. Read more here: t1p.de/xzyiu

Just kicked off COMBAT-PDAC in Barcelona!
Funded by the EU and the state of Saxony, top researchers across 🇩🇪🇫🇷🇮🇹🇪🇸 aim to tackle pancreatic cancer through biomarkers, CAR-T cells & new diagnostics.
Let’s make a difference together!
Read more: lnkd.in/e4ipxkaE
#CancerResearch #PancreaticCancer

GGA2-depletion in beta cells by Enteroviruses causes Golgi acidification, premature activation of cathepsins and alters the MHC class I immunopeptidome Enteroviruses (EVs), such as Coxsackievirus B5 (CVB5), are linked to pancreatic beta cell autoimmunity in type 1 diabetes (T1D). CVB5 infection of beta cells blocks their cap-dependent translation but...

New paper out on bioRxiv!

CVB5 viral infection in beta cells disrupts insulin secretion and alters immune responses, potentially contributing to Type 1 Diabetes. This study pinpoints how CVB5 affects maturation of insulin secretory granules and antigen presentation.

📖 Check it out here:

What a day! The 7th Joint Dresden DZG Symposium was filled with great talks, insightful discussions, and so many exciting ideas.

Big thanks to everyone who contributed to making this event such a success. Already looking forward to next year!

#7thJointDZGSymposium

What if our research institute had no international scientists? At the PLID, diversity drives innovation. Science thrives when we bring together different perspectives, skills, and experiences. Without diversity, we all lose. #DiversityMatters #InclusiveScience #VielfaltVerbindet

📢 Next #DiabetesResearchSeminar!

Join us on March 18 at 3 PM (BCUBE) for Nico Steckhan’s talk: 🗣️ "Evidence-based Digital Diabetology: Vision and Work in Progress" and discover how digital tech is shaping the future of #diabetes care! Don’t miss it!

#DigitalDiabetology #DiabetesResearch

Congratulations to you all! A well-deserved award! 🎉 Thank you for coming to #Dresden. We hope you had a great time....

That’s a wrap on the DZD NEXT Symposium and Workshop here in Dresden!

It has been an incredible few days filled with cutting-edge research, discussions, and poster presentations.

Looking forward to seeing where these ideas take us next. Until next time! #DZDNext #DiabetesResearch #PLID

Ok, let's start this thing here with my favorite 3D animation connected to our recent paper on structure and interactions of beta cell primary cilia. www.nature.com/articles/s41...
Still super ecited about cilia-axon contacts in the pancreas.

@diabresearch-dzd.bsky.social
@dzne.science
@dkfz.bsky.social
@crtd-tud.bsky.social
@kingscollegelondon.bsky.social
@www.helmholtz-munich.de
@cmcb-tud.bsky.social
@mpicbg.bsky.social
@tudresden.bsky.social

📢 REGISTRATION OPENED for the #7thJointDZGSymposium Dresden! 🌐
Join us on March 27 for an enriching experience from 1pm to 5:15pm. Don't miss this opportunity to connect, learn & engage with your local peers. Secure your spot today! 🤝
👉 events.dzne.de/event.php?vn...

Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers - Diabetologia Type 1 diabetes is an autoimmune disease characterised by the destruction of pancreatic beta cells, resulting in lifelong insulin dependence. Although exogenous insulin can maintain glycaemic control, this approach does not protect residual or replacement pancreatic beta cells from immune-mediated death. Current therapeutics designed to protect functional beta cell mass or promote beta cell proliferation and regeneration can have off-target effects, resulting in higher dose requirements and adverse side effects. Targeted drug delivery using nanocarriers has demonstrated potential for overcoming these limitations. The critical bottleneck limiting the development of beta cell-targeted therapies is a lack of highly specific beta cell markers. This review provides an overview of the use of nanocarriers for cell-targeted delivery and the current state of the field of beta cell targeting. Technologies such as systematic evolution of ligands by exponential enrichment (SELEX) aptamer selection, phage display screening, and omics datasets from human samples are highlighted as tools to identify novel beta cell-specific targets that can be combined with nanocarriers for targeted delivery of therapeutics. Ultimately, beta cell-targeted therapies using nanocarriers present a unique opportunity to develop tailored treatments for each stage of type 1 diabetes with the goal of providing individuals with treatment options that prevent further progression or reverse the course of the disease. Graphical Abstract

Jillian Collins & Nikki L. Farnsworth highlight recent advancements in active targeting of pancreatic beta cells using #Nanocarriers to develop personalised treatments for each stage of #T1D. #DiabetesResearch
tinyurl.com/34tkccm2

“The time for screening for early-stage #T1D is now!”

🎥 Discover the #aftermovie of the ‘European Alliance to Overcome Diabetes’ forum, held at the EU Parliament in Dec 2024.

As an @ihieurope.bsky.social project, we are proud to lead the charge in raising #policy and #healthcare reform.

What a special pancreatic islet! Kudos to our colleagues Yanni and Eyke for capturing this beauty!!! 🤩

👍 for #DiabetesResearch!

#ScienceIsBeautiful

Full house at our first #DiabetesResearchSeminar in 2025! 🥳
Today our speaker Vasileia Ismini Alexaki from the IKL took us on a journey into the exciting field of cellular #metabolism regulation in metabolic diseases. Thank you for sharing your insights with us! 🙏 #diabetes #research

Taking care of your diabetes is taking care of your body

Preventing and managing #diabetes complications is key to staying healthy!

🔎 Get regular eye and foot check-ups
🔎 Work with your healthcare team to manage blood pressure, blood sugar and protect your heart and kidneys.